Search
Close this search box.
Search
Close this search box.
Search
Close this search box.

Category: GLOBE-NEWSWIRE

Slovenian Tourist Board published an article exploring the highlights in Slovenia 2026

Slovenia highlights 2026 LJUBLJANA, Slovenia, Dec. 10, 2025 (GLOBE NEWSWIRE) — In 2026, Slovenia invites travelers – and storytellers – to explore a year rich in cultural milestones, outdoor adventures and experiences that redefine slow, meaningful travel. With the Slovenian Tourist Board at the helm, the country showcases everything from

Bitget Reports Record 4,468% Surge in Tokenized US Stock Futures During Earnings Season

Bitget Reports Record 4,468% Surge in Tokenized US Stock Futures During Earnings Season VICTORIA, Seychelles, Dec. 09, 2025 (GLOBE NEWSWIRE) — Bitget, the world’s largest Universal Exchange (UEX), has released new data showing unprecedented growth in global demand for tokenized US equities during the recent earnings season. From mid-October to

Mavenir Confirms Refocus Strategy on Mobile Core and AI Vision With Expanded Leadership Team to Accelerate AI-Native Network Strategy

RICHARDSON, Texas, Dec. 08, 2025 (GLOBE NEWSWIRE) — Mavenir, the software company building AI-by-design mobile networks, today announced a strong leadership team to accelerate its vision for telco-first, cloud-native, AI-by-design networks. This transformation follows the company’s recent recapitalization and aligns with a refreshed product strategy focused on mobile core, AI-enabled

Bitget October 2025 Protection Fund Maintains $741M Average Despite Slumptober

Bitget October 2025 Protection Fund Maintains $741M Average Despite Slumptober VICTORIA, Seychelles, Dec. 08, 2025 (GLOBE NEWSWIRE) — Bitget, the world’s largest Universal Exchange (UEX), today released its October 2025 Protection Fund report, recording an average monthly valuation of $741,435,710 despite a challenging month across digital asset markets. The fund

Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting

DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL)1 Zamto-cel was well-tolerated in the majority of patients. DALY 2-EU included a high-risk study population, characterized by older age and clinically high-risk disease features A 12-day manufacturing time